Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 176

Sort by

Sort Order Select

Journal Articles

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

Blood (2021) 138 (Supplement 1): 2598.

https://doi.org/10.1182/blood-2021-148876

Published: 2021

Journal Articles

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-138810

Published: 2020

Journal Articles

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Blood (2019) 134 (Supplement_1): 3308.

https://doi.org/10.1182/blood-2019-129684

Published: 2019

Journal Articles

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2019) 134 (Supplement_1): 4248.

https://doi.org/10.1182/blood-2019-127435

Published: 2019

Journal Articles

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Blood (2019) 133 (13): 1457–1464.

https://doi.org/10.1182/blood-2018-10-879866

Published: 2019

Includes: Supplemental data

Journal Articles

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

David P. Steensma, Uwe Platzbecker, Koen Van Eygen, Azra Raza, MD, Valeria Santini, Ulrich Germing, MD, Patricia Font, MD, Irina Samarina, MD, Maria Díez-Campelo, Sylvain Thepot, MD, Edo Vellenga, Mrinal M. Patnaik, MDMBBS, Jun Ho Jang, MD PhD, Jacqueline Bussolari, PhD, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Pierre Fenaux

Blood (2018) 132 (Supplement 1): 463.

https://doi.org/10.1182/blood-2018-99-114877

Published: 2018

Journal Articles

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Blood (2018) 132 (Supplement 1): 1.

https://doi.org/10.1182/blood-2018-99-110805

Published: 2018

Journal Articles

Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT

Gerbrig Berger, Leonie I. Kroeze, Theresia N. Koorenhof-Scheele, Aniek O. de Graaf, Kenichi Yoshida, Hiroo Ueno, Yuichi Shiraishi, Satoru Miyano, Eva van den Berg, Hein Schepers, Bert A. van der Reijden, Seishi Ogawa, Edo Vellenga, Joop H. Jansen

Blood (2018) 131 (16): 1846–1857.

https://doi.org/10.1182/blood-2017-09-805879

Published: 2018

Includes: Supplemental data

Journal Articles

Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial

Ruth Wester, Bronno van der Holt, Emelie Asselbergs, Sonja Zweegman, MD PhD, Marie José Kersten, MD, Edo Vellenga, MD, Marinus van Marwijk Kooij, MD PhD, Okke de Weerdt, MD, Monique C Minnema, Sarah Lonergan, Antonio Palumbo, MD, Henk M Lokhorst, Annemiek Broyl, MD PhD, Karim Saad Iskander, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 3141.

https://doi.org/10.1182/blood.V130.Suppl_1.3141.3141

Published: 2017

Journal Articles

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Blood (2017) 130 (Supplement 1): 2016.

https://doi.org/10.1182/blood.V130.Suppl_1.2016.2016

Published: 2017

Journal Articles

Putative Autophagy Protein VMP1 Amplifies Protective Autophagy Under Stress Conditions in AML Cells

Hendrik Folkerts, MSc, Albertus T.J. Wierenga, PhD, Jan Jacob Schuringa, PhD, Edo Vellenga, MD

Blood (2017) 130 (Supplement 1): 3918.

https://doi.org/10.1182/blood.V130.Suppl_1.3918.3918

Published: 2017

Journal Articles

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Geert Huls, MD PhD, Dana Chitu, Violaine Havelange, Mojca Jongen-Lavrencic, MD PhD, Arjen van de Loosdrecht, Bart J. Biemond, MD PhD, Harm Sinnege, MDPhD, Beata Hodossy, Carlos Graux, Marinus van Marwijk Kooij, MD PhD, Okke de Weerdt, MD, Dimitri Breems, MD PhD, Saskia Klein, MD, Jurgen Kuball, MD, Gert J. Ossenkoppele, MD PhD, Bob Lowenberg, MD PhD, Edo Vellenga, MD

Blood (2017) 130 (Supplement 1): 463.

https://doi.org/10.1182/blood.V130.Suppl_1.463.463

Published: 2017

Journal Articles

RUNX1 Mutations Lead to a Myeloid Differentiation Block in Association with Enhanced Proliferation By Altering the RUNX1 Transcriptional Program

Mylène Gerritsen, MSc, Esther Tijchon, PhD, Guoqiang Yi, PhD, Jorren Kuster, BSc, Jan Jacob Schuringa, PhD, Joost H.A. Martens, Edo Vellenga, MD

Blood (2017) 130 (Supplement 1): 1229.

https://doi.org/10.1182/blood.V130.Suppl_1.1229.1229

Published: 2017

Journal Articles

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

Pierre Fenaux, MD PhD, Azra Raza, MD, Edo Vellenga, MD, Uwe Platzbecker, MD, Valeria Santini, MD, Irina Samarina, MD, Koen Van Eygen, MD, Maria Díez-Campelo, MD PhD, Mrinal M. Patnaik, MDMBBS, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Aleksandra Rizo, MD PhD, David P. Steensma, MD

Blood (2017) 130 (Supplement 1): 4256.

https://doi.org/10.1182/blood.V130.Suppl_1.4256.4256

Published: 2017

Journal Articles

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Blood (2017) 129 (12): 1636–1645.

https://doi.org/10.1182/blood-2016-10-740613

Published: 2017

Includes: Supplemental data

Journal Articles

Establishing human leukemia xenograft mouse models by implanting human bone marrow–like scaffold-based niches

Antonella Antonelli, Willy A. Noort, Jenny Jaques, Bauke de Boer, Regina de Jong-Korlaar, Annet Z. Brouwers-Vos, Linda Lubbers-Aalders, Jeroen F. van Velzen, Andries C. Bloem, Huipin Yuan, Joost D. de Bruijn, Gert J. Ossenkoppele, Anton C. M. Martens, Edo Vellenga, Richard W. J. Groen, Jan Jacob Schuringa

Blood (2016) 128 (25): 2949–2959.

https://doi.org/10.1182/blood-2016-05-719021

Published: 2016

Includes: Supplemental data

Journal Articles

CITED2 Affects Leukemic Cell Survival By Interfering with p53 Activation

Katharina Mattes, MSc, Gerbrig Berger, BSc, Marjan Geugien, MSc, Joost H.A. Martens, Edo Vellenga, MD PhD, Hein Schepers, PhD

Blood (2016) 128 (22): 1542.

https://doi.org/10.1182/blood.V128.22.1542.1542

Published: 2016

Journal Articles

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Ruth Wester, Bronno van der Holt, PhD, Emelie Asselbergs, Mark van Duin, PhD, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD PhD, Edo Vellenga, MDPhD, Marinus van Marwijk Kooy, MD, Okke de Weerdt, MD, Monique Minnema, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 1141.

https://doi.org/10.1182/blood.V128.22.1141.1141

Published: 2016

Journal Articles

Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT

Blood (2016) 128 (22): 3467.

https://doi.org/10.1182/blood.V128.22.3467.3467

Published: 2016

Journal Articles

Following Autologous Stem Cell Transplantation (1 Yr) Mesenchymal Stem Cells Are Functionally Impaired with Reduced Hematopoietic Support

Catharina Hazenberg, MD, Fiona A.J. van den Heuvel, Edo Vellenga, MD PhD, Annet Z. Brouwers-Vos, Gerbrig Berger, BSc, Jan Jacob Schuringa, PhD

Blood (2016) 128 (22): 3888.

https://doi.org/10.1182/blood.V128.22.3888.3888

Published: 2016

NARROW

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT

Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Putative Autophagy Protein VMP1 Amplifies Protective Autophagy Under Stress Conditions in AML Cells

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

RUNX1 Mutations Lead to a Myeloid Differentiation Block in Association with Enhanced Proliferation By Altering the RUNX1 Transcriptional Program

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Establishing human leukemia xenograft mouse models by implanting human bone marrow–like scaffold-based niches

CITED2 Affects Leukemic Cell Survival By Interfering with p53 Activation

Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial

Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT

Following Autologous Stem Cell Transplantation (1 Yr) Mesenchymal Stem Cells Are Functionally Impaired with Reduced Hematopoietic Support

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only